Empowered Patient Podcast

Karen Jagoda

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. 3d ago ·  Bonus

    Hereditary Cancer Gene Testing with Tina Pesaran Ambry Genetics TRANSCRIPT

    Tina Pesaran, Vice President for Genomic Sciences at Ambry Genetics, a wholly owned subsidiary of Tempus AI, discusses hereditary cancer risk testing and its evolving role in precision medicine and early cancer detection. Current germline genetic testing uses multi-gene panels rather than single-gene tests, allowing identification of multiple mutations from either parent, providing a comprehensive risk profile. Advancements now make results available within days to guide treatment choices and clinical trial eligibility, and even faster for urgent surgical decisions. Tina explains, "Ambry Genetics is a germline genetic testing company. We focus on hereditary conditions, which are conditions that run in families and are usually inherited from our parents. We offer a variety of tests. Our test menu covers everything from cancer to rare diseases to cardiology and neurology. So it's the spectrum of those genetic conditions." " So, a lot of the cancers are the most common ones we talk about: breast cancer, colon cancer, and prostate cancer. Those also happen to be the most common cancers we see in men and women. Lung cancer is typically not one we put in the hereditary bucket, but all of the major cancers, including pancreatic and ovarian cancers, are very much in the hereditary space." #AmbryGenetics #TempusAI #HereditaryCancer #GeneticTesting #CARE #CancerScreening #PatientEmpowerment #HealthEquity #ClinicalTrials #MolecularDiagnostics #AIinHealthcare #GermlineTesting #PrecisionMedicine AmbryGen.com Listen to the podcast here

  2. 3d ago

    Hereditary Cancer Gene Testing with Tina Pesaran Ambry Genetics

    Tina Pesaran, Vice President for Genomic Sciences at Ambry Genetics, a wholly owned subsidiary of Tempus AI, discusses hereditary cancer risk testing and its evolving role in precision medicine and early cancer detection. Current germline genetic testing uses multi-gene panels rather than single-gene tests, allowing identification of multiple mutations from either parent, providing a comprehensive risk profile. Advancements now make results available within days to guide treatment choices and clinical trial eligibility, and even faster for urgent surgical decisions. Tina explains, "Ambry Genetics is a germline genetic testing company. We focus on hereditary conditions, which are conditions that run in families and are usually inherited from our parents. We offer a variety of tests. Our test menu covers everything from cancer to rare diseases to cardiology and neurology. So it's the spectrum of those genetic conditions." " So, a lot of the cancers are the most common ones we talk about: breast cancer, colon cancer, and prostate cancer. Those also happen to be the most common cancers we see in men and women. Lung cancer is typically not one we put in the hereditary bucket, but all of the major cancers, including pancreatic and ovarian cancers, are very much in the hereditary space." #AmbryGenetics #TempusAI #HereditaryCancer #GeneticTesting #CARE #CancerScreening #PatientEmpowerment #HealthEquity #ClinicalTrials #MolecularDiagnostics #AIinHealthcare #GermlineTesting #PrecisionMedicine AmbryGen.com Download the transcript here

  3. 3d ago ·  Bonus

    Using Continuous Physiological Monitoring and an AI-Derived Biosignature to Track Daily Depression Severity with Dr. Denis Fompeyrine MyndBlue TRANSCRIPT

    Dr. Denis Fompeyrine is the Founder and CEO of MyndBlue, a medical technology company developing an objective, continuous monitoring system that uses wearable devices to gather medical-grade biosignals to treat major depressive disorder. By collecting daily, passive measurements of depression severity, the platform can process this longitudinal data to create personalized biosignatures that enable early detection of relapse and treatment response. The technology aims to bring depression monitoring in line with monitoring chronic diseases like diabetes and other conditions with fluctuating severity. Denis explains, "Our mission is to improve treatment outcomes and help patients with major depressive disorder regain their quality of life. And to achieve this, we are offering daily monitoring of depression severity. When someone is living with depression, treatment often takes place over many months. The information we need is not only obtained during periodic assessments, because patients are living with depression every day for months, typically around eight to twelve months. Clinicians usually see their patients only every six to eight weeks for about 30 minutes."   "Our medical technology collects physiological signals during normal daily life, and we use them to monitor how the patient's condition changes over time. Patients remain under the care of their clinician, and our role is simply to provide tools that complement the clinical assessment with an objective and continuous view of how the patient evolves over time. In short, we want to give depression care what every other chronic disease already has: a daily objective measure. " #MyndBlue #MentalHealth #DigitalHealth #AIinHealthcare #HealthcareInnovation #MajorDepressiveDisorder #Depression #PTSD #WearableTechnology #Biosignatures #PrecisionMedicine #Psychiatry #VeteransHealth #Psychotherapy #RelapsePrevention #QualityOfLife #PassiveMonitoring myndblue.ai  Listen to the podcast here

  4. 3d ago

    Using Continuous Physiological Monitoring and an AI-Derived Biosignature to Track Daily Depression Severity with Dr. Denis Fompeyrine MyndBlue

    Dr. Denis Fompeyrine is the Founder and CEO of MyndBlue, a medical technology company developing an objective, continuous monitoring system that uses wearable devices to gather medical-grade biosignals to treat major depressive disorder. By collecting daily, passive measurements of depression severity, the platform can process this longitudinal data to create personalized biosignatures that enable early detection of relapse and treatment response. The technology aims to bring depression monitoring in line with monitoring chronic diseases like diabetes and other conditions with fluctuating severity. Denis explains, "Our mission is to improve treatment outcomes and help patients with major depressive disorder regain their quality of life. And to achieve this, we are offering daily monitoring of depression severity. When someone is living with depression, treatment often takes place over many months. The information we need is not only obtained during periodic assessments, because patients are living with depression every day for months, typically around eight to twelve months. Clinicians usually see their patients only every six to eight weeks for about 30 minutes."   "Our medical technology collects physiological signals during normal daily life, and we use them to monitor how the patient's condition changes over time. Patients remain under the care of their clinician, and our role is simply to provide tools that complement the clinical assessment with an objective and continuous view of how the patient evolves over time. In short, we want to give depression care what every other chronic disease already has: a daily objective measure. " #MyndBlue #MentalHealth #DigitalHealth #AIinHealthcare #HealthcareInnovation #MajorDepressiveDisorder #Depression #PTSD #WearableTechnology #Biosignatures #PrecisionMedicine #Psychiatry #VeteransHealth #Psychotherapy #RelapsePrevention #QualityOfLife #PassiveMonitoring myndblue.ai  Download the transcript here

  5. 4d ago ·  Bonus

    Simplifying Calorie and Nutrition Tracking with AI Food Scale with Kostas Koukoravas Qalzy TRANSCRIPT

    Kostas Koukoravas, Co-Founder of Qalzy, has developed an AI-powered smart kitchen scale designed to simplify nutrition tracking and address critical gaps in current food-tracking apps.  The device uses a camera to identify food items while weighing them, then matches portion data to a verified nutritional database to provide accurate data points. By scanning barcodes, reading nutrition labels, and identifying fresh ingredients, the system can track calories and macronutrients, along with key vitamins and minerals, and provide reports that can integrate into other health apps and be shared with clinicians. Kostas explains, "So the idea is that you have the scale, it's got an integrated camera on it, and literally you just press a button, it weighs and identifies your food at the same time, then matches it to an accurate verified nutritional database. We use USDA, and that allows you to get accurate nutrition information about what you're eating."   "What we consistently saw, both in our efforts and in published research, is that calorie counts in those apps can be up to 65% inaccurate. The reason is that they're missing the key information about the weight of the food, and it is very difficult to determine the weight from just a photo. What typically happens is that an app like that will estimate the standard portion you might use for an ingredient, and that standard portion might be very different from your portion." "We know from research that people who count calories or try to estimate their nutrition are very bad at eyeballing portions and at understanding the weight of a portion or the portion size the food producer intended. So we often find that people are very inaccurate in estimating their calories by just looking at a photo, and the same thing goes for these apps. It is impossible to tell the weight and therefore the calories or nutritional value of the food." #Qalzy #AIKitchenScale #SmartFoodScale #CalorieTracking #MacroTracking #NutritionTracking #FoodLogging #ProteinTracking #PortionControl #AINutrition #DigitalHealth #HealthTech #SmartKitchenScale #AINutritionTracking #AccurateCalorieCounting #NutritionData #DieticianTools #GLP1Nutrition qalzy.com Listen to the podcast here

  6. 4d ago

    Simplifying Calorie and Nutrition Tracking with AI Food Scale with Kostas Koukoravas Qalzy

    Kostas Koukoravas, Co-Founder of Qalzy, has developed an AI-powered smart kitchen scale designed to simplify nutrition tracking and address critical gaps in current food-tracking apps.  The device uses a camera to identify food items while weighing them, then matches portion data to a verified nutritional database to provide accurate data points. By scanning barcodes, reading nutrition labels, and identifying fresh ingredients, the system can track calories and macronutrients, along with key vitamins and minerals, and provide reports that can integrate into other health apps and be shared with clinicians. Kostas explains, "So the idea is that you have the scale, it's got an integrated camera on it, and literally you just press a button, it weighs and identifies your food at the same time, then matches it to an accurate verified nutritional database. We use USDA, and that allows you to get accurate nutrition information about what you're eating."   "What we consistently saw, both in our efforts and in published research, is that calorie counts in those apps can be up to 65% inaccurate. The reason is that they're missing the key information about the weight of the food, and it is very difficult to determine the weight from just a photo. What typically happens is that an app like that will estimate the standard portion you might use for an ingredient, and that standard portion might be very different from your portion." "We know from research that people who count calories or try to estimate their nutrition are very bad at eyeballing portions and at understanding the weight of a portion or the portion size the food producer intended. So we often find that people are very inaccurate in estimating their calories by just looking at a photo, and the same thing goes for these apps. It is impossible to tell the weight and therefore the calories or nutritional value of the food." #Qalzy #AIKitchenScale #SmartFoodScale #CalorieTracking #MacroTracking #NutritionTracking #FoodLogging #ProteinTracking #PortionControl #AINutrition #DigitalHealth #HealthTech #SmartKitchenScale #AINutritionTracking #AccurateCalorieCounting #NutritionData #DieticianTools #GLP1Nutrition qalzy.com Download the transcript here

  7. 4d ago ·  Bonus

    AI Clinical Decision Support Unlocks Unstructured Data with Dr. Tim O'Connell Emtelligent TRANSCRIPT

    Dr. Tim O'Connell, Co-Founder and CEO of Emtelligent, specializes in large-scale, accurate data extraction from unstructured clinical notes and text, converting documentation into structured, searchable data for clinical decision support systems. The system uses proprietary OCR, NLP APIs, and new form-filling and document-parsing capabilities to overcome the most persistent challenges in documentation and medical coding. While AI models are increasingly accurate, human oversight is considered essential in healthcare settings to ensure that new AI agentic tools are accurate and can accelerate care provider analysis.  Tim explains, "So it's definitely the Wild West out there. We use these frontier models and large language models of all different sizes and capabilities quite regularly. We've done quite a bit of benchmarking of these tools, and they are continuing to evolve, I would say. I don't necessarily think they're continuing to improve, because they often improve in some ways and not in others. Or the latest generation of the model may show regression in some areas. So they're certainly expanding their capabilities, but when it comes to clinical decision support and medicine and anything related to critical patient care pathways, very careful implementation is needed. That's for sure. And we still need humans in the loop and human oversight and all these sorts of things."   "Our core, the brain of the platform, is still our NLP API. It codes, structures, and understands all the data. We've also extended that with new capabilities, like the easy button API. You can just dump PDFs on one side and get very clean, sorted data out the other side. And we're working on new projects around form filling, question answering, and synthetic patient generation APIs. So we're quite busy. We've got a lot on the go."  #Emtelligent #MedicalAIParsing #EasyButtonAPI #SyntheticPatientGeneration #PatientAdvocacy #HealthcareAI #AIinHealthcare #DigitalHealth #ClinicalAI #FDARegulation #HealthIT #AIGovernance #HealthTech #ClinicalDecisionSupport#ClinicalDecisionSupport #ClinicalAI #MedicalAI #ClinicalInformatics #HealthIT #MedicalCoding #FrontierModels #AgenticAI #HealthcareDataExtraction #PatientSafety #FirstDoNoHarm #HumanInTheLoop #MedicalDeviceRegulation #ClinicalDocumentation #EHRData #RetrievalAugmentedGeneration #RAG #PhysicianWorkflow #HospitalAI #MedicalTranscription Emtelligent.com  Listen to the podcast here

  8. 4d ago

    AI Clinical Decision Support Unlocks Unstructured Data with Dr. Tim O'Connell Emtelligent

    Dr. Tim O'Connell, Co-Founder and CEO of Emtelligent, specializes in large-scale, accurate data extraction from unstructured clinical notes and text, converting documentation into structured, searchable data for clinical decision support systems. The system uses proprietary OCR, NLP APIs, and new form-filling and document-parsing capabilities to overcome the most persistent challenges in documentation and medical coding. While AI models are increasingly accurate, human oversight is considered essential in healthcare settings to ensure that new AI agentic tools are accurate and can accelerate care provider analysis.  Tim explains, "So it's definitely the Wild West out there. We use these frontier models and large language models of all different sizes and capabilities quite regularly. We've done quite a bit of benchmarking of these tools, and they are continuing to evolve, I would say. I don't necessarily think they're continuing to improve, because they often improve in some ways and not in others. Or the latest generation of the model may show regression in some areas. So they're certainly expanding their capabilities, but when it comes to clinical decision support and medicine and anything related to critical patient care pathways, very careful implementation is needed. That's for sure. And we still need humans in the loop and human oversight and all these sorts of things."   "Our core, the brain of the platform, is still our NLP API. It codes, structures, and understands all the data. We've also extended that with new capabilities, like the easy button API. You can just dump PDFs on one side and get very clean, sorted data out the other side. And we're working on new projects around form filling, question answering, and synthetic patient generation APIs. So we're quite busy. We've got a lot on the go."  #Emtelligent #MedicalAIParsing #EasyButtonAPI #SyntheticPatientGeneration #PatientAdvocacy #HealthcareAI #AIinHealthcare #DigitalHealth #ClinicalAI #FDARegulation #HealthIT #AIGovernance #HealthTech #ClinicalDecisionSupport#ClinicalDecisionSupport #ClinicalAI #MedicalAI #ClinicalInformatics #HealthIT #MedicalCoding #FrontierModels #AgenticAI #HealthcareDataExtraction #PatientSafety #FirstDoNoHarm #HumanInTheLoop #MedicalDeviceRegulation #ClinicalDocumentation #EHRData #RetrievalAugmentedGeneration #RAG #PhysicianWorkflow #HospitalAI #MedicalTranscription Emtelligent.com  Download the transcript here

4.9
out of 5
19 Ratings

About

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.